https://www.globenewswire.com/news-release/2023/02/21/2611806/37146/en/Amydis-Announces-Enrollment-of-Cerebral-Amyloid-Angiopathy-Participants-in-Phase-1-2a-Retinal-Tracer-Trial.html
0
0
2/21/23 at 10:00am
Organization
GlobeNewswire
39 words
0
Comments
SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable......
1 similar article
You are the first to view
Create an account
or login to join the discussion